These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28423503)

  • 21. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin.
    Yonesaka K; Tamura K; Kurata T; Satoh T; Ikeda M; Fukuoka M; Nakagawa K
    Int J Cancer; 2006 Feb; 118(4):812-20. PubMed ID: 16108013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer.
    Kala S; Mak AS; Liu X; Posocco P; Pricl S; Peng L; Wong AS
    J Med Chem; 2014 Mar; 57(6):2634-42. PubMed ID: 24592939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing Ku80 using small interfering RNA enhanced radiation sensitivity in vitro and in vivo.
    Nimura Y; Kawata T; Uzawa K; Okamura J; Liu C; Saito M; Shimada H; Seki N; Nakagawara A; Ito H; Ochiai T; Tanzawa H
    Int J Oncol; 2007 Jun; 30(6):1477-84. PubMed ID: 17487369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dual-targeting drug co-delivery system for tumor chemo- and gene combined therapy.
    Zhang F; Li M; Su Y; Zhou J; Wang W
    Mater Sci Eng C Mater Biol Appl; 2016 Jul; 64():208-218. PubMed ID: 27127046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
    Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
    Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
    Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
    Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
    Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
    Jing H; Cheng W; Li S; Wu B; Leng X; Xu S; Tian J
    Colloids Surf B Biointerfaces; 2016 Oct; 146():387-95. PubMed ID: 27388967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA.
    Cho WY; Hong SH; Singh B; Islam MA; Lee S; Lee AY; Gankhuyag N; Kim JE; Yu KN; Kim KH; Park YC; Cho CS; Cho MH
    Eur J Pharm Biopharm; 2015 Aug; 94():450-62. PubMed ID: 26141346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer.
    Liu X; Liu C; Laurini E; Posocco P; Pricl S; Qu F; Rocchi P; Peng L
    Mol Pharm; 2012 Mar; 9(3):470-81. PubMed ID: 22208617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer.
    Peng H; Yang H; Song L; Zhou Z; Sun J; Du Y; Lu K; Li T; Yin A; Xu J; Wei S
    J Exp Clin Cancer Res; 2016 Mar; 35():57. PubMed ID: 27029190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association.
    Lee E; Oh C; Kim IS; Kwon IC; Kim S
    J Control Release; 2015 Jul; 210():105-14. PubMed ID: 25979325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-delivery of doxorubicin and siRNA with reduction and pH dually sensitive nanocarrier for synergistic cancer therapy.
    Chen W; Yuan Y; Cheng D; Chen J; Wang L; Shuai X
    Small; 2014 Jul; 10(13):2678-87. PubMed ID: 24668891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the Mechanisms of Light-Triggered siRNA Release from Nanoshells for Temporal Control Over Gene Regulation.
    Riley RS; Dang MN; Billingsley MM; Abraham B; Gundlach L; Day ES
    Nano Lett; 2018 Jun; 18(6):3565-3570. PubMed ID: 29701993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
    Wang Y; Saad M; Pakunlu RI; Khandare JJ; Garbuzenko OB; Vetcher AA; Soldatenkov VA; Pozharov VP; Minko T
    Clin Cancer Res; 2008 Jun; 14(11):3607-16. PubMed ID: 18519795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo.
    Kaestner P; Aigner A; Bastians H
    Cancer Lett; 2011 May; 304(2):128-36. PubMed ID: 21377782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterial delivery of siRNAs: a new approach to solid tumor therapy.
    Xu DQ; Zhang L; Kopecko DJ; Gao L; Shao Y; Guo B; Zhao L
    Methods Mol Biol; 2009; 487():161-87. PubMed ID: 19301647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
    Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
    Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.